SCHEMBL15022969

SCHEMBL15022969

C[Si](C)(C)C#Cc1ccc(-n2ncnc2-c2ccncc2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.34
▸ FLT3 P36888 1/20 0.34
▸ GABRA1 P14867 1/20 0.34
▸ GABRG2 P18507 1/20 0.34
▸ GABRB3 P28472 1/20 0.34
▸ GABRA5 P31644 1/20 0.34
▸ GABRA3 P34903 1/20 0.34
▸ GABRA2 P47869 1/20 0.34
▸ MAPK10 P53779 5/20 0.33
▸ MAPK9 P45984 4/20 0.33
▸ GRM5 P41594 3/20 0.33
▸ MAPKAPK2 P49137 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30
▸ MAPK8 P45983 1/20 0.30
▸ EGLN2 Q96KS0 1/20 0.30
▸ TDP1 Q9NUW8 1/20 0.30
▸ BRAF P15056 1/20 0.30
▸ KDR P35968 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15022094 0.80 HDAC8 (0.44) MAPTFLT3MAPK10MAPK9GRM5
SCHEMBL15022987 0.79 MAPK9 (0.51) MAPTFLT3GABRA1GABRG2GABRB3
SCHEMBL18292376 0.79 MAPK10 (0.39) MAPTFLT3MAPK10MAPK9MAPKAPK2
SCHEMBL15022321 0.75 CYP3A4 (0.39) MAPTFLT3MAPK10MAPK9KDM4E
SCHEMBL11252379 0.75 FLT3 (0.50) MAPTFLT3ALDH1A1BRAFKDR
SCHEMBL11253060 0.75 NOTUM (0.43) MAPK10MAPK9KDM4EALDH1A1HSD17B10
SCHEMBL15022081 0.73 GRM5 (0.44) MAPK10MAPK9GRM5MAPK8
SCHEMBL15022086 0.73 MAPK9 (0.50) FLT3GABRA1GABRG2GABRB3GABRA5
SCHEMBL15022258 0.73 MAPK9 (0.51) FLT3GABRA1GABRG2GABRB3GABRA5
SCHEMBL3540534 0.70 GRM5 (0.47) MAPTGRM5ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130158031-A1 ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF SU ZHOU JING HONG BIOTECH CO., LTD. (CN) 2013-06-20 — — US disclosed
US-20130158031-A1 ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF SU ZHOU JING HONG BIOTECH CO., LTD. (CN) 2013-06-20 — — US disclosed
US-20130158031-A1 ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF SU ZHOU JING HONG BIOTECH CO., LTD. (CN) 2013-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158031-A1 ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF CHRNA10, ATXN10, SCN10A MAPT 114/4885FLT3 2887/4885GABRA1 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback